Cushing's syndrome: All variants, detection, and treatment

Endocrinology and Metabolism Clinics of North America

Volumn 40, Issue 2, 2011, Pages 379-391

  Sharma, Susmeeta T ^a   Nieman, Lynnette K ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

11 Beta hydroxysteroid dehydrogenase; Cushing's syndrome; Ectopic ACTH secretion; Glucocorticoids; Hypercortisolemia; Hypertension

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATRIAL NATRIURETIC FACTOR; BROMOCRIPTINE; CABERGOLINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE; ENDOTHELIN 1; GLUCOCORTICOID; GLUCOCORTICOID ANTAGONIST; HYDROCORTISONE; HYPERTENSIVE FACTOR; KALLIKREIN; KETOCONAZOLE; METYRAPONE; MIFEPRISTONE; MINERALOCORTICOID; MITOTANE; OCTREOTIDE; PASIREOTIDE; PROSTACYCLIN; PROSTAGLANDIN; SOMATOSTATIN; SPIRONOLACTONE; VASODILATOR AGENT;

ADRENAL INSUFFICIENCY; BLOOD PRESSURE REGULATION; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR RISK; CUSHING SYNDROME; DIZZINESS; DRUG MECHANISM; DRUG MEGADOSE; ENZYME INDUCTION; GASTROINTESTINAL DISEASE; GYNECOMASTIA; HIRSUTISM; HUMAN; HYPERALDOSTERONISM; HYPERCORTISOLISM; HYPERTENSION; LETHARGY; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SLEEP APNEA SYNDROME;

ADOLESCENT; ADULT; ANIMALS; CHILD; CUSHING SYNDROME; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; HYPERTENSION;

EID: 79955740942     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2011.01.006     Document Type: Review

References (62)

1. Lindholm J., Juul S., Jorgenson J.O., et al. Incidence and late prognosis of Cushing's syndrome: a population based study. J Clin Endocrinol Metab 2001, 86:117-123.
2. Etxabe J., Vazquez J.A. Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf) 1994, 40:479-484.
3. Newell-Price J., Bertagna X., Grossman A.B., et al. Cushing's syndrome. Lancet 2006, 367:1605-1617.
4. Catargi B., Rigalleau V., Poussin A., et al. Occult Cushing's syndrome in type-2 diabetes. J Clin Endocrinol Metab 2003, 88:5808-5813.
5. Leibowitz G., Tsur A., Chayen S.D., et al. Pre-clinical Cushing's syndrome: an unexpected frequent cause of poor glycaemic control in obese diabetic patients. Clin Endocrinol (Oxf) 1996, 44:717-722.
6. Nugent C.A., Warner H.R., Dunn J.T., et al. Probability theory in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 1964, 24:621-627.
7. Ross E.J., Linch D.C. Cushing's syndrome-killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet 1982, 2(8299):646-649.
8. Magiakou M.A., Mastorakos G., Oldfield E.H., et al. Cushing's syndrome in children and adolescents: presentation, diagnosis, and therapy. N Engl J Med 1994, 331:629-636.
9. Nieman L.K., Biller B.M., Findling J.W., et al. The diagnosis of Cushing's syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008, 93(5):1526-1540.
10. Nieman L.K., Ilias I. Evaluation and treatment of Cushing's syndrome. Am J Med 2005, 118:134-146.
11. Ilias I., Torpy D.J., Pacak K., et al. Cushing's syndrome due to ectopic corticotrophin secretion: twenty years experience at National Institutes of Health. J Clin Endocrinol Metab 2005, 90:4955-4962.
12. Torpy D.J., Mullen N., Ilias I., et al. Association of hypertension and hypokalemia with Cushing's syndrome caused by ectopic ACTH secretion. Ann N Y Acad Sci 2002, 970:134-144.
13. Faggiano A., Pivonello R., Spiezia S., et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 2003, 88:2527-2533.
14. Stewart P.M., Walker B.R., Holder F. II beta-hydroxysteroid dehydrogenase activity in Cushing's syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1995, 80:3617-3620.
15. Magiakou M.A., Mastorakos G., Zachman K., et al. Blood pressure in children and adolescents with Cushing's syndrome before and after surgical cure. J Clin Endocrinol Metab 1997, 82:1734-1738.
16. Treadwell B.L.J., Sever E.D., Savage O., et al. Side-effects of long-term treatment with corticosteroids and corticotrophin. Lancet 1964, 1(7343):1121-1123.
17. Fraser R., Davies D.L., Connell J.M. Hormones and hypertension. Clin Endocrinol 1989, 31:701-746.
18. Chobanian A.V., Bakris G.L., Black H.R., et al. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension 2003, 42:1206-1252.
19. Lewington S., Clarke R., Qizilbash N., et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360(9349):1903-1913.
20. Speiker C., Barenbrock M., Rahn K.H., et al. Circadian blood pressure variations in endocrine disorders. Blood Press 1993, 2:35-39.
21. Imai Y., Abe S., Sasaki S., et al. Altered circadian blood pressure rhythm in patients with Cushing's syndrome. Hypertension 1988, 12:11-19.
22. Zacharieva S., Orbetzova M., Stoynev A., et al. Circadian blood pressure profile in patients with Cushing's syndrome before and after treatment. J Endocrinol Invest 2004, 27:924-930.
23. Imai Y., Abe S., Sasaki S., et al. Exogenous glucocorticoid eliminates or reverses circadian blood pressure variations. J Hypertens 1989, 7:113-120.
24. Magiakou M.A., Smyrnaki P., Chrousos G.P. Hypertension in Cushing's syndrome. Best Pract Res Clin Endocrinol Metab 2006 Sep, 20(3):467-482.
25. Quinkler M., Stewart P.M. Hypertension and the Cortisol-Cortisone shuttle. J Clin Endocrinol Metab 2003, 88(6):2384-2392.
26. Hatakeyama H., Inaba S., Miyamori I. 11 beta hydroxysteroid dehydrogenase in cultured human vascular cells: possible role in development of hypertension. Hypertension 1999, 33:1179-1184.
27. Brem A., Bina R., King T., et al. Localization of 2 11-betahydroxysteroid dehydrogenase isoforms in aortic endothelial cells. Hypertension 1998, 31:459-462.
28. Edwards C.R., Stewart P.M., Burt D., et al. Localization of 11-beta hydroxysteroid dehydrogenase - tissue specific protector of the mineralocorticoid receptor. Lancet 1988, 2(8618):986-989.
29. Funder J.W., Pearce P.T., Smith R., et al. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988, 242:583-585.
30. Dotsch J., Dorr H.G., Stall G.K., et al. Effect of glucocorticoid excess on cortisol/cortisone ratio. Steroids 2001, 66:817-820.
31. Ulick S., Wang J.Z., Blumenfeld J.D., et al. Cortisol inactivation overload: a mechanism of mineralocorticoid hypertension in the ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1992, 74:963-967.
32. Connell J.M., Whitworth J.A., Davies D.L., et al. Hemodynamic, hormonal, and renal effects of adrenocorticotrophic hormone in sodium-restricted man. J Hypertens 1988, 6(1):17-23.
33. Williamson P.M., Kelly J.J., Whitworth J.A. Dose-response and mineralocorticoid activity in cortisol-induced hypertension in humans. J Hypertens Suppl 1996, 14(5):S37-S41.
34. Whitworth J.A., Gordon D., Andrews J., et al. The hypertensive effect of synthetic glucocorticoids in man: role of sodium and volume. J Hypertens 1989, 7:537-549.
35. Nieman L.K., Chrousos G.P., Kellner C., et al. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 1985, 61:536-540.
36. Klett C., Ganten D., Hellmann W., et al. Regulation of hepatic angiotensinogen synthesis and secretion by steroid hormones. Endocrinology 1992, 130:3660-3668.
37. Sato A., Suzuki H., Murakami M., et al. Glucocorticoid increases angiotensin II type 1 receptor and its gene expression. Hypertension 1994, 23:25-30.
38. Shelat S.G., King J.L., Flanagan-Cato L.M., et al. Mineralocorticoids and glucocorticoids cooperatively increase salt intake and angiotensin II receptor binding in rat brain. Neuroendocrinology 1999, 69:339-351.
39. Scheuer D.A., Bechtold A.G. Glucocorticoids potentiate central actions of angiotensin to increase arterial blood pressure. Am J Physiol Regul Integr Comp Physiol 2001, 280:R1719-R1726.
40. Sala C., Ambrosi B., Morganti A. Blunted vascular and renal effects of exogenous atrial natriuretic peptide in patients with Cushing's disease. J Clin Endocrinol Metab 2001, 86:1957-1961.
41. Yasunari K., Kohno M., Murakawa K., et al. Glucocorticoids and atrial natriuretic factor receptors on vascular smooth muscle. Hypertension 1990, 16:581-586.
42. Kelm M. The L-arginine-nitric oxide pathway in hypertension. Curr Hypertens Rep 2003, 5:80-86.
43. Axelrod L. Inhibition of prostacyclin production mediates permissive effect of glucocorticoids on vascular tone. Perturbations of this mechanism contribute to pathogenesis of Cushing's syndrome and Addison's disease. Lancet 1983, 23:904-906.
44. Handa M., Kondo K., Suzuki H., et al. Role of prostaglandins and pressure sensitivity to norepinephrine. Hypertension 1984, 6(2):236-241.
45. McKnight J.A., Rooney D.P., Whitehead H., et al. Blood pressure responses to phenylephrine infusions in subjects with Cushing's syndrome. J Hum Hypertens 1995, 9:855-858.
46. Pirpiris M., Sudhir K., Yeung S., et al. Pressor responsiveness in corticosteroid-induced hypertension in humans. Hypertension 1992, 19(6):567-574.
47. Kirilov G., Tomova A., Dakovska L., et al. Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushing's syndrome. Eur J Endocrinol 2003, 149:549-553.
48. Ruschitzka F., Quaschning T., Noll G., et al. Endothelin-1 type A receptor antagonism prevents vascular dysfunction and hypertension induced by 11 beta hydroxysteroid dehydrogenase inhibition: role of nitric oxide. Circulation 2001, 103(25):3129-3135.
49. Smith L., Smith J.B. Regulation of sodium-calcium exchanger by glucocorticoids and growth factors in vascular smooth muscle. J Biol Chem 1994, 269(44):27527-27531.
50. Kelly J.J., Martin A., Whitworth J.A. Role of erythropoietin in cortisol-induced hypertension. J Hum Hypertens 2000, 14(3):195-198.
51. Shipley J.E., Schteingart D.E., Tandon R., et al. Sleep architecture and sleep apnoea in patients with Cushing's disease. Sleep 1992, 15:514-518.
52. Nieman L.K. Medical therapy of Cushing's disease. Pituitary 2002, 5:77-82.
53. Suri D., Weiss R.E. Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease. J Clin Endocrinol Metab 2005, 90(3):1340-1346.
54. Kreutzer J., Jeske I., Hofmann B., et al. No effect of the PPAR-gamma agonist rosiglitazone on ACTH or cortisol secretion in Nelson's syndrome or Cushing's disease in vitro and in vivo. Clin Neuropathol 2009, 28(6):430-439.
55. Zacharieva S., Orbetzova M., Natchev E., et al. Losartan in Cushing's syndrome. Methods Find Exp Clin Pharmacol 1998, 20:163-168.
56. Dalakos T.G., Elias A.N., Anderson G.H., et al. Evidence for an angiotensinogenic mechanism of the hypertension of Cushing's syndrome. J Clin Endocrinol Metab 1978, 46:114-118.
57. Zacharieva S., Torbova S., Orbetzova M., et al. Trandolapril in Cushing's disease: short-term trandolapril treatment in patients with Cushing's disease and essential hypertension. Methods Find Exp Clin Pharmacol 1988, 20:433-438.
58. Baid S., Nieman L.K. Glucocorticoid excess and hypertension. Curr Hypertens Rep 2004, 6(6):493-499.
59. Fallo F., Paoletta A., Tona F., et al. Response of hypertension to conventional antihypertensive treatment and/or steroidogenesis inhibitors in Cushing's syndrome. J Intern Med 1993, 234:595-598.
60. Fallo F., Sonino N., Barzon L., et al. Effect of surgical treatment on hypertension in Cushing's syndrome. Am J Hypertens 1996, 9:77-80.
61. Colao A., Pivonello R., Spiezia S., et al. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab 1999, 84:2664-2672.
62. Mishra A.K., Agarwal A., Gupta S., et al. Outcome of adrenalectomy for Cushing's syndrome: experience from a tertiary care center. World J Surg 2007, 31(7):1425-1432.